| Secondary |
| Hypertension |
40.6% |
| Product Used For Unknown Indication |
26.1% |
| Depression |
10.1% |
| Headache |
7.2% |
| Herpes Zoster |
5.8% |
| Atrial Fibrillation |
2.9% |
| Prophylaxis |
2.9% |
| Prostate Cancer |
2.9% |
| Hypertension Arterial |
1.4% |
|
| Hypotension |
29.2% |
| Syncope |
20.8% |
| Biliary Colic |
8.3% |
| Sinus Bradycardia |
8.3% |
| Visual Acuity Reduced |
8.3% |
| Anxiety |
4.2% |
| Drug Interaction |
4.2% |
| Overdose |
4.2% |
| Therapeutic Agent Toxicity |
4.2% |
| Tongue Oedema |
4.2% |
| Urinary Tract Infection |
4.2% |
|
| Concomitant |
| Hypertension |
20.2% |
| Product Used For Unknown Indication |
19.0% |
| Drug Use For Unknown Indication |
10.2% |
| Coronary Artery Disease |
6.5% |
| Diabetes Mellitus |
5.8% |
| Prophylaxis |
5.2% |
| Non-small Cell Lung Cancer |
4.8% |
| Rheumatoid Arthritis |
4.0% |
| Atrial Fibrillation |
2.7% |
| Benign Prostatic Hyperplasia |
2.5% |
| Premedication |
2.5% |
| Type 2 Diabetes Mellitus |
2.5% |
| Thrombosis Prophylaxis |
2.3% |
| Multiple Myeloma |
2.1% |
| Depression |
1.9% |
| Hepatocellular Carcinoma |
1.9% |
| Hypothyroidism |
1.7% |
| Ankylosing Spondylitis |
1.5% |
| Hypercholesterolaemia |
1.5% |
| Osteoporosis |
1.5% |
|
| Atrial Fibrillation |
9.6% |
| Pelvic Fracture |
8.2% |
| Pulmonary Embolism |
8.2% |
| Cerebral Ischaemia |
5.5% |
| Lupus-like Syndrome |
5.5% |
| Rectal Haemorrhage |
5.5% |
| Vomiting |
5.5% |
| Diabetic Foot |
4.1% |
| General Physical Health Deterioration |
4.1% |
| Hepatotoxicity |
4.1% |
| International Normalised Ratio Increased |
4.1% |
| Muscle Atrophy |
4.1% |
| Myocardial Infarction |
4.1% |
| Neutropenia |
4.1% |
| Osteonecrosis Of Jaw |
4.1% |
| Pneumonia |
4.1% |
| Presyncope |
4.1% |
| Renal Failure Acute |
4.1% |
| Renal Failure Chronic |
4.1% |
| Acute Myocardial Infarction |
2.7% |
|
| Interacting |
| Hypertension |
75.0% |
| Dyspnoea Exertional |
25.0% |
|
| Renal Failure Acute |
33.3% |
| Sinus Arrest |
33.3% |
| Urinary Incontinence |
33.3% |
|
